All In Biotech

Free tool

FAERS Monitor: Synalar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 012787 or its brand name (Synalar, Fluocinolone Acetonide). Reports on generic versions are filed under their own applications.

Reports

1,919

Serious

865

45% of reports

Hospitalization

333

Death reported

53

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus191
  • drug ineffective182
  • rash152
  • diarrhoea120
  • off label use113
  • fatigue103
  • psoriasis102
  • headache97
  • pain97
  • nausea88
  • dermatitis atopic81
  • product use in unapproved indication78
  • dry skin74
  • product dose omission issue74
  • arthralgia71

Reports by year received

View as table
YearReports
20049
200518
20067
200713
200811
200918
201020
201132
201234
201328
201430
201559
201693
201785
201895
2019130
2020137
2021139
2022168
2023194
2024185
2025223
2026191

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,240 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dermatitis atopicSignal8116.913.61,194
psoriasisSignal1028.67.1678
dry skinSignal746.14.9311
pruritusSignal1915.44.8702
rashSignal1523.83.3321
product use in unapproved indicationSignal783.52.8135
product dose omission issueSignal742.82.282
diarrhoeaSignal1202.01.764
arthralgia711.91.529
pain971.71.430
headache971.71.428
drug ineffective1821.51.333
fatigue1031.51.214
off label use1131.41.214
nausea881.21.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.